Quick Summary:
Unveiling a comprehensive examination of an ever-growing sphere, this market research report anticipates the global Benign Prostatic Hyperplasia (BPH) Drugs market to reach $9.8 Billion by 2030. The notable surge in value from $6.3 Billion in 2022 underlines the industry's commendable growth prospects, further fuelled by emerging economies and significant technological advancements.
The report presents a detailed exploration of various market segments, with a focus on Alpha-Blockers, projected to reach a commendable $6.7 Billion by 2030. Grasp the opportunity to better understand the market dynamics in leading economies such as the USA and China, while also gaining insights into the growth potential spread across Europe, Japan, and Canada. Remain informed about the strategic actions and positions of major competitors like ADC Therapeutics, Boehringer Ingelheim, and GlaxoSmithKline, amongst others. Gaining access to this report ensures you stay ahead in this vibrant and evolving market landscape.
Global Benign Prostatic Hyperplasia (BPH) Drugs Market to Reach $9.8 Billion by 2030
The global market for Benign Prostatic Hyperplasia (BPH) Drugs estimated at US$6.3 Billion in the year 2022, is projected to reach a revised size of US$9.8 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2022-2030. Alpha-Blockers, one of the segments analyzed in the report, is projected to record 6% CAGR and reach US$6.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the 5-ARIs segment is readjusted to a revised 5.1% CAGR for the next 8-year period.
The U.S. Market is Estimated at $1.9 Billion, While China is Forecast to Grow at 5.3% CAGR
The Benign Prostatic Hyperplasia (BPH) Drugs market in the U.S. is estimated at US$1.9 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 5.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.5% and 4.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.Select Competitors (Total 18 Featured) -
- ADC Therapeutics SA
- Advaxis, Inc.
- Agennix AG
- ANI Pharmaceuticals, Inc.
- Astellas Pharma, Inc.
- Bayer Healthcare AG
- BHR Pharma, LLC.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Eli Lilly and Company
- Endo Pharmaceuticals, Inc.
- Ferring Pharmaceuticals, Inc.
- Foresee Pharmaceuticals Co., Ltd.
- GlaxoSmithKline PLC
- Io Therapeutics Inc.
- LIDDS AB (publ)
- Madrigal Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Novartis AG
- Nymox Pharmaceutical Corporation
- Sanofi
- Spectrum Pharmaceuticals
- Takeda Pharmaceuticals Company Ltd.
- Teva Pharmaceutical Industries Ltd.
- Urologix, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Benign Prostatic Hyperplasia (BPH) Drugs?
What is the growth rate of the Global Market for Benign Prostatic Hyperplasia (BPH) Drugs?
What is the forecasted size of the Global Market for Benign Prostatic Hyperplasia (BPH) Drugs?
Who are the key companies in the Global Market for Benign Prostatic Hyperplasia (BPH) Drugs?
| Report Attribute | Details |
|---|---|
| No. of Pages | 182 |
| Published | November 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 6.3 Billion |
| Forecasted Market Value ( USD | $ 9.8 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- ADC Therapeutics SA
- Advaxis, Inc.
- Agennix AG
- ANI Pharmaceuticals, Inc.
- Astellas Pharma, Inc.
- Bayer Healthcare AG
- BHR Pharma, LLC.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Eli Lilly and Company
- Endo Pharmaceuticals, Inc.
- Ferring Pharmaceuticals, Inc.
- Foresee Pharmaceuticals Co., Ltd.
- GlaxoSmithKline PLC
- Io Therapeutics Inc.
- LIDDS AB (publ)
- Madrigal Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Novartis AG
- Nymox Pharmaceutical Corporation
- Sanofi
- Spectrum Pharmaceuticals
- Takeda Pharmaceuticals Company Ltd.
- Teva Pharmaceutical Industries Ltd.
- Urologix, Inc.
